Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Proposed Offering and Amendments, Patents, Results, and Announcements by Healthcare Companies - Research Report on Forest



   Proposed Offering and Amendments, Patents, Results, and Announcements by
   Healthcare Companies - Research Report on Forest Laboratories, OncoMed,
                      EnteroMedics, Cadence, and Amarin

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 6, 2013

NEW YORK, December 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Forest
Laboratories Inc. (NYSE: FRX), OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED),
EnteroMedics, Inc. (NASDAQ: ETRM), Cadence Pharmaceuticals Inc. (NASDAQ:
CADX), and Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Forest Laboratories Inc. Research Report

On December 2, 2013, Forest Laboratories Inc. (Forest Laboratories) announced
a proposed offering of $1 billion aggregate principal amount of senior
unsecured fixed rate notes due 2021. According to Forest Laboratories, the
Company intends to use the net proceeds from the offering of the notes to fund
the Company's proposed accelerated share repurchase initiative and the
remainder for general corporate purposes, which include potential acquisitions
and additional share buybacks. The Company also announced its entry into an
amendment to its existing undrawn $750 million revolving credit facility with
JPMorgan Chase Bank and other lenders, which aims to amend the definition of
Consolidated EBITDA to adjust for certain cost savings for the purposes of
calculating Forest Laboratories' leverage ratio and interest coverage ratio.
The Company further stated that the restrictive agreements covenant was also
amended to allow Forest Laboratories to incur additional indebtedness with
lien restrictions that are customary for similarly rated US companies and that
are not materially more restrictive than the restrictions in the $750 million
credit agreement. The Full Research Report on Forest Laboratories Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea24_FRX

--

OncoMed Pharmaceuticals, Inc. Research Report

On December 3, 2013, OncoMed Pharmaceuticals, Inc.'s (OncoMed Pharmaceuticals)
stock jumped significantly by 97.86%, closing the day at $27.70 per share. The
Company's stock increased by 111.61% over the previous three trading days,
compared to the Dow Jones Industrial Average which decreased by 1.14% during
the same trading period. The Full Research Report on OncoMed Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a95c_OMED

--

EnteroMedics, Inc. Research Report

On December 3, 2013, EnteroMedics, Inc. (EnteroMedics) announced the Company's
18 month efficacy and safety results from its 5 year ReCharge Pivotal Trial of
VBLOC®. According to the Company, patients in the VBLOC group (n=117),
achieved excess weight loss (EWL) of 25%, or 10% total body weight loss (TBL),
compared to 12% EWL or 4% TBL for sham control group patients (n=42).
Additionally, the Company stated that the 13% difference in EWL demonstrates
statistical superiority over sham control and, in total, 54% of patients in
the VBLOC group achieved at least 20% EWL while 41% achieved at least 25% EWL,
compared to 26% and 17% respectively, for the sham control group, during the
same 18-month period. Commenting on the results, Mark B. Knudson, Ph.D.,
EnteroMedics' President and CEO stated, "These study results, along with
multi-year data from our earlier clinical trials, demonstrate durability of
effect and a superior record of safety, underscoring the attractive benefit
risk profile of VBLOC Therapy. If approved, VBLOC may help to address the
lifelong challenges associated with obesity by offering a treatment option
that supports safe, long-term weight loss and a healthy lifestyle." The Full
Research Report on EnteroMedics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/d32d_ETRM

--

Cadence Pharmaceuticals Inc. Research Report

On December 3, 2013, Cadence Pharmaceuticals Inc.'s (Cadence Pharmaceuticals)
stock was up by 6.15%, at $10.01 per share. The Company's stock went up by
12.09% over the past three trading days, compared to the Nasdaq Composite
which went down by 0.19% during the same trading period. The Full Research
Report on Cadence Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/f5e5_CADX

--

Amarin Corporation plc Research Report

On December 2, 2013, Amarin Corporation plc (Amarin) announced that the United
States Patent and Trademark Office (USPTO) has published notification of
Notices of Allowance for the Company's U.S. Patent Applications Serial Numbers
13/685,281, and 13/685,291, each titled "Stable Pharmaceutical Composition and
Methods of Using Same." According to the Company, the claims in the allowed
applications cover methods of lowering triglycerides by administering a
pharmaceutical composition comprised of a mixture of free fatty acids,
including EPA and/or DHA to varying degrees, to patients with severe
hypertriglyceridemia (the MARINE population) and in patients with
hypertriglyceridemia on concomitant statin therapy (the ANCHOR population).
Amarin informed that the notice of allowance is issued after the USPTO makes a
determination that patent can be granted from an application, and that the
issued patents would have terms that expire no earlier than 2030. Amarin also
stated that the applications are part of the Company's expanding patent
portfolio with 38 patent applications now either issued or allowed with the
USPTO and over 30 additional applications pending in the US. The Full Research
Report on Amarin Corporation plc - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7cf9_AMRN

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement